Method Development for Analysis of Cyclodextrin Inclusion Complexes with HPLC
DOI:
https://doi.org/10.62951/ijhm.v1i4.91Keywords:
Cyclodextrin inclusion complexes, HPLC, method development, validation, pharmaceuticalsAbstract
Cyclodextrin inclusion complexes have been widely used in the pharmaceutical industry to improve drug solubility and bioavailability. Analysis of these complexes using HPLC requires the development of appropriate and validated methods. To analyze and compare various HPLC methods used for the analysis of cyclodextrin inclusion complexes, and to identify challenges and trends in method development. A literature review was conducted of articles published in the last 10 years, focusing on HPLC methods for the analysis of cyclodextrin inclusion complexes. Parameters compared included column type, mobile phase composition, flow rate, and detection method. The majority of studies used C18 columns with varying lengths and particle sizes. The composition of the mobile phase varied, reflecting the diversity of properties of the complexes analyzed. The flow rate was generally 1.0 mL/min, with the exception of the HPLC/MS method. Detection methods included UV-Vis, PDA, fluorescence, and mass spectrometry. The main challenges included the dynamic equilibrium of the complexes and stability during analysis HPLC method development for the analysis of cyclodextrin inclusion complexes requires optimization of various parameters to overcome specific challenges. Future trends are towards the use of advanced technologies such as UHPLC and high-resolution mass detection.
Downloads
References
Banerjee, S., & Mazumdar, S. (2020). Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte. International Journal of Analytical Chemistry, 2020.
Bosînceanu, A., Păduraru, O. M., Vasile, C., Popovici, I., Țântaru, G., & Ochiuz, L. (2013). Validation of a new HPLC method used for determination of amiodarone from the complex with hydroxypropyl-beta-cyclodextrin and from commercial tablets. Farmacia, 61(1), 175-183.
Braga, S. S., Lysenko, K., El-Saleh, F., & Paz, F. A. A. (2021). Cyclodextrin-Efavirenz Complexes Investigated by Solid State and Solubility Studies. MDPI AG, 15.
Brewster, M. E., & Loftsson, T. (2017). Cyclodextrins as pharmaceutical solubilizers. Advanced Drug Delivery Reviews, 59(7), 645-666.
Chang, C., Song, M., Ma, M., Song, J., Cao, F., & Qin, Q. (2023). Preparation, Characterization and Molecular Dynamics Simulation of Rutin–Cyclodextrin Inclusion Complexes. Molecules, 28(3).
Chen, J., Lu, W. L., Gu, W., Lu, S. S., Chen, Z. P., & Cai, B. C. (2016). Drug-in-cyclodextrin-in-liposomes: A promising delivery system for hydrophobic drugs. Expert Opinion on Drug Delivery, 13(10), 1457-1469.
Creteanu, A., Pamfil, D., Vasile, C., Tantaru, G., Ghiciuc, C. M., & Ochiuz, L. (2019). Study on the Role of the Inclusion Complexes with 2-Hydroxypropyl-β-cyclodextrin for Oral Administration of Amiodarone. International Journal of Polymer Science, 2019.
Dahiya, S., Kaushik, A., & Pathak, K. (2015). Improved pharmacokinetics of aceclofenac immediate release tablets incorporating its inclusion complex with hydroxypropyl-β-cyclodextrin. Scientia Pharmaceutica, 83(3), 501-510.
Del Valle, E. M. (2018). Cyclodextrins and their uses: a review. Process Biochemistry, 39(9), 1033-1046.
Desai, C., & Prabhakar, B. (2015). Development and evaluation of orally disintegrating tablets of cilostazol-β-cyclodextrin inclusion complexes. Drug Development and Industrial Pharmacy, 41(10), 1589-1607.
Ding, Y., Pang, Y., Vara Prasad, C. V. N. S., & Wang, B. (2020). Formation of inclusion complex of enrofloxacin with 2-hydroxypropyl-β-cyclodextrin. Drug Delivery, 27(1), 334-343.
Dong, M. W. (2019). HPLC and UHPLC for practicing scientists. John Wiley & Sons.
Fekete, S., Kohler, I., Rudaz, S., & Guillarme, D. (2017). Importance of instrumentation for fast liquid chromatography in pharmaceutical analysis. Journal of Pharmaceutical and Biomedical Analysis, 130, 3-13.
García-Campaña, A. M., Baeyens, W. R., Zhang, X., Alés, F., & Gámiz, L. (2019). Unfamiliar though exciting analytical detection in flowing streams: chemiluminescence. European Journal of Pharmaceutical Sciences, 20(4-5), 425-441.
Gidwani, B., & Vyas, A. (2019). A comprehensive review on cyclodextrin-based carriers for delivery of chemotherapeutic cytotoxic anticancer drugs. BioMed Research International, 2019.
Iacovino, R., Caso, J. V., Rapuano, F., Russo, A., Isidori, M., Lavorgna, M., Malgieri, G., & Isernia, C. (2020). Cyclodextrin inclusion complexes: NMR and computational studies. Current Organic Chemistry, 21(14), 1403-1422.
International Conference on Harmonisation. (2021). ICH harmonised tripartite guideline: validation of analytical procedures: text and methodology Q2(R1).
Jadhav, P., Petkar, B., Pore, Y., Kulkarni, A., & Burade, K. (2013). Physicochemical and molecular modeling studies of cefixime-l-arginine-cyclodextrin ternary inclusion compounds. Carbohydrate Polymers, 98(2), 1317-1325.
Jambhekar, S. S., & Breen, P. (2022). Cyclodextrins in pharmaceutical formulations I: structure and physicochemical properties, formation of complexes, and types of complex. Drug Discovery Today, 21(2), 356-362.
Jansook, P., Ogawa, N., & Loftsson, T. (2018). Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. International Journal of Pharmaceutics, 535(1-2), 272-284.
Kang DW, Kim SH. Clinical aspects of splenomegaly as a possible predictive factor of coronary artery changes in Kawasaki disease. Cardiol Young. 2019 Mar;29(3):297-302
Kazakevich, Y., & LoBrutto, R. (2018). HPLC for pharmaceutical scientists. John Wiley & Sons.
Kurkov, S. V., & Loftsson, T. (2020). Cyclodextrins. International Journal of Pharmaceutics, 453(1), 167-180.
Loftsson, T., & Brewster, M. E. (2020). Pharmaceutical applications of cyclodextrins: basic science and product development. Journal of Pharmacy and Pharmacology, 62(11), 1607-1621.
Loftsson, T., & Brewster, M. E. (2021). Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. Journal of Pharmacy and Pharmacology, 63(9), 1119-1135.
Loftsson, T., & Duchêne, D. (2018). Cyclodextrins and their pharmaceutical applications. International Journal of Pharmaceutics, 329(1-2), 1-11.
Maggio, R. M., Vignaduzzo, S. E., & Kaufman, T. S. (2020). Practical and regulatory considerations for stability-indicating methods for the assay of bulk drugs and drug formulations. TrAC Trends in Analytical Chemistry, 49, 57-70.
Marcolino, A. I. P., Scheeren, L. E., Nogueira-Librelotto, D. R., Fernandes, J. R., Adams, A. I. H., De Carvalho, L. M., & Oliveira, L. F. S. (2019). Establishment of a stability indicating HPLC method for dronedarone hydrochloride in tablets and in cyclodextrin inclusion complexes: application to degradation kinetic studies. Chemical Papers, 73(4), 871-881.
Mendes, C., Costa, A. P., Oliveira, P. R., Tagliari, M. P., & Silva, M. A. S. (2015). Physicochemical and microbiological stability studies of extemporaneous antihypertensive pediatric suspensions for hospital use. Pharmaceutical Development and Technology, 20(2), 209-215.
Moldoveanu, S., & David, V. (2016). Selection of the HPLC method in chemical analysis. Elsevier.
Muchtaridi, M., Triwahyuningtyas, D., Muhammad Fakih, T., Megantara, S., & Choi, S. B. (2023). Mechanistic insight of α-mangostin encapsulation in 2-hydroxypropyl-β-cyclodextrin for solubility enhancement. Journal of Biomolecular Structure and Dynamics.
Mura, P. (2017). Analytical techniques for characterization of cyclodextrin complexes in aqueous solution: A review. Journal of Pharmaceutical and Biomedical Analysis, 101, 238-250.
Nguyen Y, Stirnemann J, Belmatoug N. La maladie de Gaucher : quand y penser ? [Gaucher disease: A review]. Rev Med Interne. 2019 May; 40(5):313-322.
Nováková, L., & Vlčková, H. (2019). A review of current trends and advances in modern bio-analytical methods: chromatography and sample preparation. Analytica Chimica Acta, 656(1-2), 8-35.
Papaioannou, A., Christoforides, E., & Bethanis, K. (2020). Inclusion complexes of naringenin in dimethylated and permethylated β-cyclodextrins: Crystal structures and molecular dynamics studies. Crystals, 10(1).
Popielec, A., & Loftsson, T. (2021). Effects of cyclodextrins on the chemical stability of drugs. International Journal of Pharmaceutics, 531(2), 532-542.
Rácz, A., Bajusz, D., & Héberger, K. (2021). Life beyond the Tanimoto coefficient: similarity measures for interaction fingerprints. Journal of Cheminformatics, 10(1), 48.
Sahu, P. K., Ramisetti, N. R., Cecchi, T., Swain, S., Patro, C. S., & Panda, J. (2018). An overview of experimental designs in HPLC method development and validation. Journal of Pharmaceutical and Biomedical Analysis, 147, 590-611.
Saokham, P., Muankaew, C., Jansook, P., & Loftsson, T. (2020). Solubility of cyclodextrins and drug/cyclodextrin complexes. Molecules, 23(5), 1161.
Schellinger, A. P., & Carr, P. W. (2016). Isocratic and gradient elution chromatography: a comparison in terms of speed, retention reproducibility and quantitation. Journal of Chromatography A, 1109(2), 253-266.
Swartz, M. E. (2017). UPLC™: An introduction and review. Journal of Liquid Chromatography & Related Technologies, 28(7-8), 1253-1263.
Szejtli, J. (2019). Introduction and general overview of cyclodextrin chemistry. Chemical Reviews, 98(5), 1743-1754.
Szente, L., Szemán, J., & Sohajda, T. (2023). Analytical characterization of cyclodextrins: History, official methods and recommended new techniques. Journal of Pharmaceutical and Biomedical Analysis, 147, 13-23.
Tiwari, G., Tiwari, R., & Rai, A. K. (2022). Cyclodextrins in delivery systems: Applications. Journal of Pharmacy and Bioallied Sciences, 2(2), 72-79.
Uekama, K., Hirayama, F., & Irie, T. (2018). Cyclodextrin drug carrier systems. Chemical Reviews, 98(5), 2045-2076.
Yan, H., Zhang, J., Ren, C., & Tang, F. (2021). Application of cyclodextrin in cancer treatment. Current Pharmaceutical Biotechnology, 22(2), 175-188.
Zhang, J., & Ma, P. X. (2020). Cyclodextrin-based supramolecular systems for drug delivery: Recent progress and future perspective. Advanced Drug Delivery Reviews, 65(9), 1215-1233.
Zidovetzki, R., & Levitan, I. (2017). Use of cyclodextrins to manipulate plasma membrane cholesterol content: evidence, misconceptions and control strategies. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1768(6), 1311-1324.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 International Journal of Health and Medicine
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
